The Allevi Liver dECM promises the fabrication of liver tissue that has a more representative physiological function. The product uses a combination of a type I collagen Allevi bioink for patterning as well as Xylyx Bio’s highly desired liver-specific TissueSpec® ECM to enhance specialized biological response.
Xylyx Bio products for cell culture are obtained from porcine or human tissue sources and processed to various formats, enabling cell culture models that are significantly more predictive of physiology. Their 3D TissueSpec® ECM hydrogels and scaffolds provide support to cell culture models, facilitating the acceleration of drug discovery, development and tissue regeneration.
“We are thrilled to partner with Allevi and share our expertise in tissue-specific ECM,” stated Andrea Nye, Chief Executive Officer at Xylyx Bio. “Recognizing the importance of the native cellular microenvironment, Xylyx Bio harnesses the body’s innate biology in the form of tissue-specific extracellular matrix. By sourcing extracellular matrix from native organs and tissues, Xylyx produces tissue-specific substrates that comprise both the mechanical properties and complex ratios of ECM components specific and unique to each tissue and organ type.”
Founded in 2014, Allevi claims that its “mission is to provide users the ability to design, engineer, and manufacture 3D tissue.” To deliver important building blocks and provide users with the best experience possible to drive new scientific discoveries, Allevi is hopeful that the new dECM bioink will provide scientists a revolutionary approach that allows scientists to print 3D tissue structures with biochemical and mechanical features inherent in human physiology.
[Images: Allevi and Xylyx Bio]
Xylyx Bio’s Co-founder and Chief Strategy Officer, John O’Neil, added that a “deeper understanding of the comprehensive nature of tissues and cells and their interaction with the cellular microenvironment – that is, the extracellular matrix – holds great promise to lead to a paradigm shift in 3D bioprinting, allowing researchers to study physiologic activity of cells in vitro towards a better understanding of disease and development of more effective drugs and treatments.”
You May Also Like
3D Printing for COVID-19, Part Seven: New 3D-Printed Parts and Partners
Corporate, government and individual efforts to use additive manufacturing (AM) to address the medical supply shortages resulting from the COVID-19 outbreak are continuing. We continue to stress that the industry...
3D Printing for COVID-19, Part Six: Government Regulations and Outreach
As a country with a strong centralized government, China was able to enact a quarantine and manufacture supplies quickly compared to nations with weaker or decentralized governance structures. From that...
3D Printing for COVID-19, Part Five: Face Shields and Masks
As a hospitalist mentioned in a previous post on the efforts of 3D printing companies to address the coronavirus outbreak, some 3D printed parts may be safer and easier to...
3D Printing for COVID-19, Part Three: Open Source Ventilators
Since the initial news flurry about how a network of Italian 3D printing users came to the rescue of a hospital on the front lines of the COVID-19 outbreak in...
View our broad assortment of in house and third party products.